Zynerba Pharmaceuticals, Inc.

ZYNE


Canadian symbol: ZYNE
US symbol: ZYNE

Currency in USD

Valuation Measures4

Market Cap (intraday) 72.28M
Enterprise Value 36.53M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)1.15k
Price/Book (mrq)2.49
Enterprise Value/Revenue 397.61
Enterprise Value/EBITDA -0.95

Trading Information

Stock Price History

Beta (5Y Monthly) 1.32
52-Week Change 363.41%
S&P500 52-Week Change 318.47%
52 Week High 31.4000
52 Week Low 30.2500
50-Day Moving Average 30.8967
200-Day Moving Average 30.5654

Share Statistics

Avg Vol (3 month) 3886.21k
Avg Vol (10 day) 3786.11k
Shares Outstanding 553.94M
Implied Shares Outstanding 653.94M
Float 835.45M
% Held by Insiders 16.07%
% Held by Institutions 112.13%
Shares Short (Aug 30, 2023) 4240.62k
Short Ratio (Aug 30, 2023) 40.15
Short % of Float (Aug 30, 2023) 40.48%
Short % of Shares Outstanding (Aug 30, 2023) 40.45%
Shares Short (prior month Jul 30, 2023) 440.73k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2022
Most Recent Quarter (mrq)Jun 29, 2023

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-45.11%
Return on Equity (ttm)-87.13%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -38.56M
Net Income Avi to Common (ttm)-37.58M
Diluted EPS (ttm)-0.8000
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)35.97M
Total Cash Per Share (mrq)0.71
Total Debt (mrq)217.88k
Total Debt/Equity (mrq)0.75%
Current Ratio (mrq)3.43
Book Value Per Share (mrq)0.57

Cash Flow Statement

Operating Cash Flow (ttm)-31.64M
Levered Free Cash Flow (ttm)-18.79M

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Cannabis Market and Business News

Real-time cannabis business news from hundreds of sources. Never miss the news that matters the most.

All Stock News Financials Mergers & Acquisitions Joint Ventures IPO Analysts Trading Halts
All Business News Cannabis Politics News Hemp News Legalization News Science & Studies CBD & Medical News



Company News Date
ZYNE
Zynerba Pharmaceuticals
1 month ago   -   greenmarketreport
greenmarketreport
1 month ago
ZYNE
Zynerba Pharmaceuticals
1 month ago   -   greenmarketreport
greenmarketreport
1 month ago
ZYNE
Zynerba Pharmaceuticals
1 month ago   -   benzinga
benzinga
1 month ago
ZYNE
Zynerba Pharmaceuticals
1 month ago   -   news
news
1 month ago
ZYNE
Zynerba Pharmaceuticals
4 months ago   -   news
news
4 months ago
ZYNE
Zynerba Pharmaceuticals
4 months ago   -   benzinga
benzinga
4 months ago
ZYNE
Zynerba Pharmaceuticals
6 months ago   -   news
news
6 months ago
ZYNE
Zynerba Pharmaceuticals
8 months ago   -   benzinga
benzinga
8 months ago
ZYNE
Zynerba Pharmaceuticals
9 months ago   -   news
news
9 months ago
ZYNE
Zynerba Pharmaceuticals
9 months ago   -   benzinga
benzinga
9 months ago
ZYNE
Zynerba Pharmaceuticals
10 months ago   -   ca
ca
10 months ago
ZYNE
Zynerba Pharmaceuticals
11 months ago   -   greenmarketreport
greenmarketreport
11 months ago
ZYNE
Zynerba Pharmaceuticals
1 year ago   -   greenmarketreport
greenmarketreport
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago   -   benzinga
benzinga
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago   -   greenmarketreport
greenmarketreport
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago   -   benzinga
benzinga
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago   -   ca
ca
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago   -   ca
ca
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago   -   benzinga
benzinga
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago   -   benzinga
benzinga
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago   -   benzinga
benzinga
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago   -   benzinga
benzinga
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago   -   ca
ca
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago   -   seekingalpha
seekingalpha
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago   -   conejovalleyobserver
conejovalleyobserver
1 year ago
ZYNE
Zynerba Pharmaceuticals
2 years ago   -   ca
ca
2 years ago
ZYNE
Zynerba Pharmaceuticals
2 years ago   -   greenmarketreport
greenmarketreport
2 years ago
ZYNE
Zynerba Pharmaceuticals
2 years ago   -   ca
ca
2 years ago
ZYNE
Zynerba Pharmaceuticals
2 years ago   -   mccourier
mccourier
2 years ago
ZYNE
Zynerba Pharmaceuticals
2 years ago   -   ir
ir
2 years ago
ZYNE
Zynerba Pharmaceuticals
2 years ago   -   theglobeandmail
theglobeandmail
2 years ago
ZYNE
Zynerba Pharmaceuticals
2 years ago   -   marketrealist
marketrealist
2 years ago
ZYNE
Zynerba Pharmaceuticals
2 years ago   -   bnnbloomberg
bnnbloomberg
2 years ago
ZYNE
Zynerba Pharmaceuticals
2 years ago   -   finance
finance
2 years ago
ZYNE
Zynerba Pharmaceuticals
2 years ago   -   seekingalpha
seekingalpha
2 years ago
ZYNE
Zynerba Pharmaceuticals
2 years ago   -   seekingalpha
seekingalpha
2 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago   -   greenmarketreport
greenmarketreport
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago   -   greenmarketreport
greenmarketreport
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago   -   benzinga
benzinga
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago   -   benzinga
benzinga
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago   -   mjobserver
mjobserver
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago   -   finance
finance
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago   -   seekingalpha
seekingalpha
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago   -   finance
finance
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago   -   finance
finance
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago   -   benzinga
benzinga
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago   -   benzinga
benzinga
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago   -   finance
finance
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago   -   finance
finance
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago   -   finance
finance
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago   -   benzinga
benzinga
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago   -   finance
finance
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago   -   benzinga
benzinga
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago   -   greenmarketreport
greenmarketreport
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago   -   greenmarketreport
greenmarketreport
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago   -   finance
finance
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago   -   finance
finance
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago   -   seekingalpha
seekingalpha
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago   -   finance
finance
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago   -   finance
finance
3 years ago
ZYNE
Zynerba Pharmaceuticals
3 years ago   -   finance
finance
3 years ago
ZYNE
Zynerba Pharmaceuticals
4 years ago   -   seekingalpha
seekingalpha
4 years ago
ZYNE
Zynerba Pharmaceuticals
4 years ago   -   finance
finance
4 years ago
ZYNE
Zynerba Pharmaceuticals
4 years ago   -   finance
finance
4 years ago
ZYNE
Zynerba Pharmaceuticals
4 years ago   -   finance
finance
4 years ago
ZYNE
Zynerba Pharmaceuticals
4 years ago   -   finance
finance
4 years ago
ZYNE
Zynerba Pharmaceuticals
4 years ago   -   finance
finance
4 years ago
ZYNE
Zynerba Pharmaceuticals
4 years ago   -   finance
finance
4 years ago
ZYNE
Zynerba Pharmaceuticals
4 years ago   -   finance
finance
4 years ago
ZYNE
Zynerba Pharmaceuticals
4 years ago   -   finance
finance
4 years ago
ZYNE
Zynerba Pharmaceuticals
4 years ago   -   finance
finance
4 years ago
ZYNE
Zynerba Pharmaceuticals
4 years ago   -   greenmarketreport
greenmarketreport
4 years ago
ZYNE
Zynerba Pharmaceuticals
4 years ago   -   finance
finance
4 years ago
ZYNE
Zynerba Pharmaceuticals
4 years ago   -   finance
finance
4 years ago
ZYNE
Zynerba Pharmaceuticals
4 years ago   -   finance
finance
4 years ago
ZYNE
Zynerba Pharmaceuticals
4 years ago   -   finance
finance
4 years ago
ZYNE
Zynerba Pharmaceuticals
4 years ago   -   finance
finance
4 years ago
ZYNE
Zynerba Pharmaceuticals
4 years ago   -   finance
finance
4 years ago
ZYNE
Zynerba Pharmaceuticals
4 years ago   -   marijuanastocks
marijuanastocks
4 years ago
ZYNE
Zynerba Pharmaceuticals
4 years ago   -   marijuanastocks
marijuanastocks
4 years ago
ZYNE
Zynerba Pharmaceuticals
4 years ago   -   finance
finance
4 years ago
ZYNE
Zynerba Pharmaceuticals
4 years ago   -   finance
finance
4 years ago
ZYNE
Zynerba Pharmaceuticals
4 years ago   -   finance
finance
4 years ago
ZYNE
Zynerba Pharmaceuticals
4 years ago   -   finance
finance
4 years ago
ZYNE
Zynerba Pharmaceuticals
4 years ago   -   finance
finance
4 years ago
ZYNE
Zynerba Pharmaceuticals
4 years ago   -   seekingalpha
seekingalpha
4 years ago
ZYNE
Zynerba Pharmaceuticals
4 years ago   -   seekingalpha
seekingalpha
4 years ago
ZYNE
Zynerba Pharmaceuticals
4 years ago   -   finance
finance
4 years ago
ZYNE
Zynerba Pharmaceuticals
4 years ago   -   finance
finance
4 years ago
ZYNE
Zynerba Pharmaceuticals
4 years ago   -   finance
finance
4 years ago
ZYNE
Zynerba Pharmaceuticals
4 years ago   -   finance
finance
4 years ago
ZYNE
Zynerba Pharmaceuticals
4 years ago   -   finance
finance
4 years ago
ZYNE
Zynerba Pharmaceuticals
4 years ago   -   finance
finance
4 years ago
ZYNE
Zynerba Pharmaceuticals
4 years ago   -   finance
finance
4 years ago
ZYNE
Zynerba Pharmaceuticals
4 years ago   -   finance
finance
4 years ago
ZYNE
Zynerba Pharmaceuticals
4 years ago   -   finance
finance
4 years ago
ZYNE
Zynerba Pharmaceuticals
4 years ago   -   finance
finance
4 years ago
ZYNE
Zynerba Pharmaceuticals
4 years ago   -   finance
finance
4 years ago
ZYNE
Zynerba Pharmaceuticals
4 years ago   -   finance
finance
4 years ago
ZYNE
Zynerba Pharmaceuticals
4 years ago   -   finance
finance
4 years ago
ZYNE
Zynerba Pharmaceuticals
4 years ago   -   finance
finance
4 years ago
ZYNE
Zynerba Pharmaceuticals
4 years ago   -   finance
finance
4 years ago
ZYNE
Zynerba Pharmaceuticals
4 years ago   -   finance
finance
4 years ago
ZYNE
Zynerba Pharmaceuticals
4 years ago   -   finance
finance
4 years ago
ZYNE
Zynerba Pharmaceuticals
4 years ago   -   finance
finance
4 years ago
ZYNE
Zynerba Pharmaceuticals
4 years ago   -   finance
finance
4 years ago
ZYNE
Zynerba Pharmaceuticals
4 years ago   -   finance
finance
4 years ago
ZYNE
Zynerba Pharmaceuticals
4 years ago   -   finance
finance
4 years ago
ZYNE
Zynerba Pharmaceuticals
4 years ago   -   finance
finance
4 years ago
ZYNE
Zynerba Pharmaceuticals
4 years ago   -   finance
finance
4 years ago
ZYNE
Zynerba Pharmaceuticals
4 years ago   -   finance
finance
4 years ago
ZYNE
Zynerba Pharmaceuticals
4 years ago   -   finance
finance
4 years ago
ZYNE
Zynerba Pharmaceuticals
4 years ago   -   finance
finance
4 years ago
Order by date
Order by relevance

Currency in USD
Earnings EstimateCurrent Qtr. (Sep 2023)Next Qtr. (Dec 2023)Current Year (2023)Next Year (2024)
No. of Analysts4434
Avg. Estimate0.09-0.21-0.84-0.63
Low Estimate-0.22-0.24-0.88-1.03
High Estimate0.97-0.19-0.81-0.18
Year Ago EPS-0.2-0.18-0.82-0.84
Revenue EstimateCurrent Qtr. (Sep 2023)Next Qtr. (Dec 2023)Current Year (2023)Next Year (2024)
No. of Analysts4434
Avg. Estimate15MN/AN/A11.25M
Low EstimateN/AN/AN/AN/A
High Estimate60MN/AN/A45M
Year Ago SalesN/AN/AN/AN/A
Sales Growth (year/est)N/AN/AN/AN/A
Earnings History2022-09-292022-12-302023-03-302023-06-29
EPS Est.-0.22-0.18-0.19-0.2
EPS Actual-0.2-0.18-0.21-0.21
Difference0.020-0.02-0.01
Surprise %9.10%0.00%-10.50%-5.00%
EPS TrendCurrent Qtr. (Sep 2023)Next Qtr. (Dec 2023)Current Year (2023)Next Year (2024)
Current Estimate0.09-0.21-0.84-0.63
7 Days Ago0.09-0.21-0.84-0.63
30 Days Ago0.09-0.21-0.84-0.63
60 Days Ago-0.2-0.18-0.76-0.61
90 Days Ago-0.2-0.18-0.76-0.61
EPS RevisionsCurrent Qtr. (Sep 2023)Next Qtr. (Dec 2023)Current Year (2023)Next Year (2024)
Up Last 7 DaysN/AN/AN/AN/A
Up Last 30 DaysN/AN/AN/AN/A
Down Last 7 DaysN/AN/AN/AN/A
Down Last 30 DaysN/AN/AN/AN/A
Growth EstimatesZYNEIndustrySector(s)S&P 500
Current Qtr.145.00%N/AN/AN/A
Next Qtr.-16.70%N/AN/AN/A
Current Year-2.40%N/AN/AN/A
Next Year25.00%N/AN/AN/A
Next 5 Years (per annum)N/AN/AN/AN/A
Past 5 Years (per annum)N/AN/AN/AN/A


Insiders transactions are updated every hour.
Insider Roster
Insider Transactions

Major Holders

Currency in USD
Breakdown
6.07%% of Shares Held by All Insider
12.13%% of Shares Held by Institutions
12.91%% of Float Held by Institutions
52Number of Institutions Holding Shares

Top Institutional Holders

HolderSharesDate Reported% OutValue
Vanguard Group Inc2,179,600Jun 29, 20234.04%2,920,664
Blackrock Inc.740,524Jun 29, 20231.37%992,302
ETF Managers Group, LLC723,151Mar 30, 20231.34%969,022
Renaissance Technologies, LLC689,713Jun 29, 20231.28%924,215
Geode Capital Management, LLC387,346Jun 29, 20230.72%519,043
Penserra Capital Management LLC220,858Jun 29, 20230.41%295,949
Millennium Management Llc125,835Jun 29, 20230.23%168,618
Two Sigma Advisers, LP124,000Jun 29, 20230.23%166,160
State Street Corporation119,741Jun 29, 20230.22%160,452
Northern Trust Corporation115,210Jun 29, 20230.21%154,381

Top Mutual Fund Holders

HolderSharesDate Reported% OutValue
Vanguard Total Stock Market Index Fund1,521,801Jun 29, 20232.82%2,039,213
Vanguard Extended Market Index Fund604,155Jun 29, 20231.12%809,567
Fidelity Extended Market Index Fund238,972May 30, 20230.44%320,222
Amplify Seymour Cannabis ETF219,146Apr 29, 20230.41%293,655
Fidelity Total Market Index Fund56,274May 30, 20230.10%75,407
Bridgeway Funds Inc-Ultra Small Company Market Fund52,200Jun 29, 20230.10%69,948
Fidelity Series Total Market Index Fund44,979May 30, 20230.08%60,271
Schwab Capital Trust-Total Stock Market Index Fund37,596Apr 29, 20230.07%50,378
Vanguard Balanced Index Fund37,481Jun 29, 20230.07%50,224
iShares Core S&P Total U.S. Stock Market ETF34,168Aug 30, 20230.06%45,785
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by Zynerba Pharmaceuticals, Inc.


Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Symposium
CalendarPress Release59 views5 min read

Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Symposium

Zynerba Pharmaceuticals
DEVON, Pa., Sept. 14, 2023 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, announces an oral presentation at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Symposium, being he... Read More...
Zynerba Pharmaceuticals Announces New Date for Reconvened Annual Meeting
Press Release55 views3 min read

Zynerba Pharmaceuticals Announces New Date for Reconvened Annual Meeting

Zynerba Pharmaceuticals
DEVON, Pa., July 25, 2023 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) (the “Company”), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that the new date for the adjourned 2023 Annual Meeting of Stockholders (“Annual Meeting”) is August 11, 2023... Read More...
Zynerba Pharmaceuticals Announces Further Adjournment of Annual Meeting
CalendarPress Release60 views4 min read

Zynerba Pharmaceuticals Announces Further Adjournment of Annual Meeting

Zynerba Pharmaceuticals
Annual Meeting Reconvened and Adjourned Without Conducting Business Meeting to Reconvene on July 27, 2023 at 9:00 am EDT DEVON, Pa., June 28, 2023 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) (the “Company”), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, toda... Read More...
Zynerba Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
Press Release42 views4 min read

Zynerba Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference

Zynerba Pharmaceuticals
DEVON, Pa., June 20, 2023 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba, will present at the H.C. Wainwright 4th Annual Neuropsyc... Read More...
Zynerba Pharmaceuticals Announces Partial Adjournment of Annual Meeting
CalendarPress Release61 views4 min read

Zynerba Pharmaceuticals Announces Partial Adjournment of Annual Meeting

Zynerba Pharmaceuticals
Meeting adjourned with respect to Proposal 2, Reverse Stock Split; Company encourages additional stockholders of record to vote before reconvened meeting on June 28, 2023 All other proposals approved DEVON, Pa., June 13, 2023 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) (the “Company”), the leader in innovative pharmaceutically-produce... Read More...
Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
FinancialsPress Release71 views16 min read

Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights

Zynerba Pharmaceuticals
<!-- Name:DistributionId Value:8796417 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4577 --> <!-- Name:CustomerId Value:1028868 --> <!-- Name:HasMediaSnippet Value:false --> <!-- Name:AnalyticsTrackingId Value:6fba109a-36ab-4b39-9299-839060711d7f --> Enrollment con... Read More...
Zynerba Pharmaceuticals Announces Publication in the Journal of Neurodevelopmental Disorders Describing the Role of the Endocannabinoid System and Cannabidiol Therapy in Fragile X Syndrome
Press Release76 views8 min read

Zynerba Pharmaceuticals Announces Publication in the Journal of Neurodevelopmental Disorders Describing the Role of the Endocannabinoid System and Cannabidiol Therapy in Fragile X Syndrome

Zynerba Pharmaceuticals
Comprehensive data review suggests a central role for the endocannabinoid system (ECS) in neuronal development, cognitive function and in the pathogenesis of Fragile X syndrome (FXS) Cannabidiol may help restore the function of the ECS in FXS patients according to review of data Consistent with the proposed mechanisms of action of cannabi... Read More...
Zynerba Pharmaceuticals Announces Update on RECONNECT, the Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome
Press Release74 views6 min read

Zynerba Pharmaceuticals Announces Update on RECONNECT, the Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome

Zynerba Pharmaceuticals
RECONNECT initial screening visits are being adversely impacted by environmental factors, such as the “Tripledemic” (high rates of RSV, influenza and COVID-19); topline results now expected first half of 2024 Cash runway extended to mid-year 2024 due to prioritization of resources on the completion of the RECONNECT trial DEVON, Pa., Dec.... Read More...
Zynerba Pharmaceuticals Announces Positive Long-Term Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at the Annual Meeting of the American College of Neuropsychopharmacology
Press Release24 views5 min read

Zynerba Pharmaceuticals Announces Positive Long-Term Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at the Annual Meeting of the American College of Neuropsychopharmacology

Zynerba Pharmaceuticals
Zygel™ achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments and was generally well-tolerated through 38 weeks of treatment DEVON, Pa., Dec. 05, 2022 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid... Read More...
Zynerba Pharmaceuticals Announces Poster Presentation at the Annual Meeting of the American College of Neuropsychopharmacology
Press Release161 views4 min read

Zynerba Pharmaceuticals Announces Poster Presentation at the Annual Meeting of the American College of Neuropsychopharmacology

Zynerba Pharmaceuticals
DEVON, Pa., Nov. 29, 2022 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced the presentation of a poster at the 61st Annual Meeting of the American College of Neuropsychopharmacology, being held Decemb... Read More...
Zynerba Pharmaceuticals Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygel™ in the Journal of Neurodevelopmental Disorders
Press Release60 views8 min read

Zynerba Pharmaceuticals Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygel™ in the Journal of Neurodevelopmental Disorders

Zynerba Pharmaceuticals
Study finds patients with Fragile X who have a highly methylated FMR1 gene that were treated with Zygel showed a significant reduction in behavioral symptoms compared to those treated with placebo Topline results from follow-on RECONNECT confirmatory pivotal Phase 3 trial of Zygel in patients with a completely methylated FMR1 gene expecte... Read More...
Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel™ in 22q11.2 Deletion Syndrome
Press Release40 views6 min read

Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel™ in 22q11.2 Deletion Syndrome

Zynerba Pharmaceuticals
DEVON, Pa., Nov. 15, 2022 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that the European Commission (EC) has granted orphan drug designation to cannabidiol, the active ingredient in its transderma... Read More...
Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel™ for the Treatment of 22q11.2 Deletion Syndrome
Press Release44 views4 min read

Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel™ for the Treatment of 22q11.2 Deletion Syndrome

Zynerba Pharmaceuticals
DEVON, Pa., Nov. 02, 2022 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that the U.S. Patent and Trademark Office has issued Patent No. 11,458,109, titled “Treatment of 22q11.2 Deletion Syndrome Wi... Read More...
Zynerba Pharmaceuticals Announces Poster Presentation at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit
Press Release123 views4 min read

Zynerba Pharmaceuticals Announces Poster Presentation at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit

Zynerba Pharmaceuticals
DEVON, Pa., Oct. 10, 2022 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced the presentation of a poster at the 2022 National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Br... Read More...
Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel™
Press Release48 views4 min read

Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel™

Zynerba Pharmaceuticals
DEVON, Pa., Oct. 06, 2022 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that the U.S. Patent and Trademark Office has issued Patent No. 11,458,110, titled “Treatment of Fragile X Syndrome With Cann... Read More...
Zynerba Pharmaceuticals to Present at the Ladenburg Thalmann Healthcare Conference
Press Release60 views4 min read

Zynerba Pharmaceuticals to Present at the Ladenburg Thalmann Healthcare Conference

Zynerba Pharmaceuticals
DEVON, Pa., Sept. 22, 2022 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present at the Ladenburg Thalmann ... Read More...
Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q at The Society for the Study of Behavioural Phenotypes (SSBP) 24th International Research Symposium
CalendarPress Release52 views5 min read

Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q at The Society for the Study of Behavioural Phenotypes (SSBP) 24th International Research Symposium

Zynerba Pharmaceuticals
DEVON, Pa., Sept. 08, 2022 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, announces an oral presentation at The Society for the Study of Behavioural Phenotypes (SSBP) 24th International Research Symposium, being he... Read More...
Zynerba Pharmaceuticals to Present In-Person at the H.C. Wainwright 24th Annual Global Investment Conference
CalendarPress Release54 views4 min read

Zynerba Pharmaceuticals to Present In-Person at the H.C. Wainwright 24th Annual Global Investment Conference

Zynerba Pharmaceuticals
DEVON, Pa., Sept. 06, 2022 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present in-person at the H.C. Wain... Read More...
Zynerba Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Highlights
FinancialsPress Release69 views45 min read

Zynerba Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Highlights

Zynerba Pharmaceuticals
Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome (FXS); topline results expected second-half 2023 Announced positive topline results from Phase 2 trial of Zygel in patients with 22q11.2 deletion syndrome (22q) Company focusing resources on orphan neuropsychiatric disorde... Read More...
Zynerba Pharmaceuticals to Present In Person at the Canaccord Genuity 42nd Annual Growth Conference
Press Release54 views4 min read

Zynerba Pharmaceuticals to Present In Person at the Canaccord Genuity 42nd Annual Growth Conference

Zynerba Pharmaceuticals
DEVON, Pa., Aug. 03, 2022 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present an overview and update of t... Read More...
Zynerba Pharmaceuticals Announces Positive Top Line Results from Open-Label Phase 2 INSPIRE Trial of Zygel™ in 22q11.2 Deletion Syndrome
Press Release47 views24 min read

Zynerba Pharmaceuticals Announces Positive Top Line Results from Open-Label Phase 2 INSPIRE Trial of Zygel™ in 22q11.2 Deletion Syndrome

Zynerba Pharmaceuticals
– The INSPIRE trial achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments – – Safety data reinforce excellent tolerability profile of Zygel – – Company will focus resources on FXS and 22q development – – Cash runway extended through the end of 2023 / early 2024 – – Zynerba... Read More...
Zynerba Pharmaceuticals Presents Data on Zygel™ at the American Society of Clinical Psychopharmacology Annual Meeting
Press Release47 views5 min read

Zynerba Pharmaceuticals Presents Data on Zygel™ at the American Society of Clinical Psychopharmacology Annual Meeting

Zynerba Pharmaceuticals
– Poster presentation highlights design enhancements incorporated into pivotal RECONNECT trial – – Oral presentation demonstrates long-term safety and potential effectiveness of Zygel in children and adolescents with Fragile X syndrome – DEVON, Pa., June 01, 2022 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative ph... Read More...
Zynerba Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Highlights
FinancialsPress Release54 views27 min read

Zynerba Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Highlights

Zynerba Pharmaceuticals
– Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome (FXS); topline results expected second-half 2023 – – Topline results from Phase 2 trial of Zygel in patients with 22q11.2 deletion syndrome (22q) expected mid-year 2022 – – $69.7 million in cash and cash equivalents at M... Read More...
Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel™ in Children and Adolescents with Fragile X Syndrome (FXS) at the International Society for Autism Research Annual Meeting
Press Release44 views5 min read

Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel™ in Children and Adolescents with Fragile X Syndrome (FXS) at the International Society for Autism Research Annual Meeting

Zynerba Pharmaceuticals
– Data support the long-term safety and effectiveness of Zygel – – Greatest improvements seen in those with complete methylation of their FMR1 gene – DEVON, Pa., May 11, 2022 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsy... Read More...
Zynerba Pharmaceuticals Announces Podium Presentation at the International Society for Autism Research Annual Meeting
Press Release45 views4 min read

Zynerba Pharmaceuticals Announces Podium Presentation at the International Society for Autism Research Annual Meeting

Zynerba Pharmaceuticals
DEVON, Pa., May 09, 2022 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced an oral podium presentation at the International Society for Autism Research Annual Meeting (INSAR 2022), being he... Read More...
Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel™ in Children and Adolescents with Fragile X Syndrome (FXS) at the 2022 Society of Biological Psychiatry Annual Meeting
Press Release39 views4 min read

Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel™ in Children and Adolescents with Fragile X Syndrome (FXS) at the 2022 Society of Biological Psychiatry Annual Meeting

Zynerba Pharmaceuticals
DEVON, Pa., May 02, 2022 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, presented a poster at the 2022 Society of Biological Psychiatry (SOBP) Annual Meeting, held April 28-30, 2022, in New Orleans, La.... Read More...
Zynerba Pharmaceuticals Announces Presentation of Poster at the 2022 Society of Biological Psychiatry Annual Meeting
Press Release52 views4 min read

Zynerba Pharmaceuticals Announces Presentation of Poster at the 2022 Society of Biological Psychiatry Annual Meeting

Zynerba Pharmaceuticals
DEVON, Pa., April 21, 2022 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the presentation of a poster at the 2022 Society of Biological Psychiatry (SOBP) Annual Meeting, being held Apri... Read More...
Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights
FinancialsPress Release51 views33 min read

Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights

Zynerba Pharmaceuticals
– European Commission granted orphan drug designation for Zygel™ in Fragile X syndrome (FXS) – – Continued enrollment in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel in patients with FXS; topline results expected second-half 2023 – – Completed enrollment in Phase 2 trial of Zygel in patients with 22q11.2 deletion syndrome (22q... Read More...
Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel™ in Fragile X Syndrome
Press Release70 views5 min read

Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel™ in Fragile X Syndrome

Zynerba Pharmaceuticals
DEVON, Pa., Feb. 28, 2022 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that the European Commission (EC) has granted orphan drug designation to cannabidiol, the active ingredient in it... Read More...
Zynerba Pharmaceuticals Announces Completion of Enrollment in Phase 2 Trial of Zygel™ in 22q11.2 Deletion Syndrome
Press Release78 views5 min read

Zynerba Pharmaceuticals Announces Completion of Enrollment in Phase 2 Trial of Zygel™ in 22q11.2 Deletion Syndrome

Zynerba Pharmaceuticals
DEVON, Pa., Feb. 28, 2022 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the completion of enrollment for the 14-week Phase 2 INSPIRE (Assessing the Impact of Zygel on Pediatric Behavi... Read More...
Zynerba Pharmaceuticals Announces Planned Retirement of Suzanne Hanlon and Appoints Albert P. Parker as Chief Legal Officer
Press Release50 views4 min read

Zynerba Pharmaceuticals Announces Planned Retirement of Suzanne Hanlon and Appoints Albert P. Parker as Chief Legal Officer

Zynerba Pharmaceuticals
DEVON, Pa., Feb. 15, 2022 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the appointment of Albert P. Parker, an accomplished industry executive with over 25 years of pharmaceutical, bio... Read More...
Zynerba Pharmaceuticals Announces Clinical Development Updates for FXS, ASD, 22q and DEE
Press Release56 views8 min read

Zynerba Pharmaceuticals Announces Clinical Development Updates for FXS, ASD, 22q and DEE

Zynerba Pharmaceuticals
– Company plans to focus development of Zygel™ in FXS, ASD and 22q – – Company plans to initiate Phase 3 trial with Zygel in ASD in the second half of 2022 – – Zynerba to hold conference call tomorrow, January 5, 2022 at 9:00 a.m. ET – DEVON, Pa., Jan. 04, 2022 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative phar... Read More...
Zynerba Pharmaceuticals Announces Presentation at The BRAIN Foundation Synchrony 2021 Symposium
Press Release54 views4 min read

Zynerba Pharmaceuticals Announces Presentation at The BRAIN Foundation Synchrony 2021 Symposium

Zynerba Pharmaceuticals
DEVON, Pa., Dec. 06, 2021 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced presentation details for The BRAIN Foundation Synchrony 2021 Symposium, being held virtually December 11-12, 2021... Read More...
Zynerba Pharmaceuticals Announces Issuance of New Patent in EU for Zygel™
Press Release46 views4 min read

Zynerba Pharmaceuticals Announces Issuance of New Patent in EU for Zygel™

Zynerba Pharmaceuticals
DEVON, Pa., Nov. 22, 2021 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that the European Patent Office has issued Patent No. 3687513, titled “Treatment of Fragile X Syndrome and Autism... Read More...
Zynerba Pharmaceuticals Announces Presentations at Two Upcoming Scientific Conferences in October
Press Release40 views6 min read

Zynerba Pharmaceuticals Announces Presentations at Two Upcoming Scientific Conferences in October

Zynerba Pharmaceuticals
DEVON, Pa., Oct. 21, 2021 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced oral and poster presentations at the Society for Developmental & Behavioral Pediatrics Annual Meeting, being ... Read More...
Zynerba Pharmaceuticals Announces Presentation of Poster at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit
Press Release41 views4 min read

Zynerba Pharmaceuticals Announces Presentation of Poster at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit

Zynerba Pharmaceuticals
DEVON, Pa., Oct. 19, 2021 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the presentation of a poster at the 2021 National Organization for Rare Disorders (NORD) Rare Diseases and Orphan... Read More...
Zynerba Pharmaceuticals Announces Presentation of Poster at the 2021 American Academy of Pediatrics National Conference & Exhibition
Press Release30 views4 min read

Zynerba Pharmaceuticals Announces Presentation of Poster at the 2021 American Academy of Pediatrics National Conference & Exhibition

Zynerba Pharmaceuticals
DEVON, Pa., Oct. 08, 2021 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the presentation of a poster at the 2021 American Academy of Pediatrics (AAP) National Conference & Exhibitio... Read More...
Zynerba Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference
CalendarPress Release61 views2 min read

Zynerba Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference

Zynerba Pharmaceuticals
DEVON, Pa., Sept. 20, 2021 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba, will participate in a fireside chat during ... Read More...
Zynerba Pharmaceuticals Initiates RECONNECT, a Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome
Press Release38 views7 min read

Zynerba Pharmaceuticals Initiates RECONNECT, a Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome

Zynerba Pharmaceuticals
Trial will evaluate the efficacy and safety of Zygel in children and adolescents with Fragile X Syndrome Topline results expected in second half of 2023 DEVON, Pa., Sept. 13, 2021 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare n... Read More...
Zynerba Pharmaceuticals Presents Longer Term Tolerability and Efficacy Data of Zygel™ in Children and Adolescents with Autism Spectrum Disorder (ASD) at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021
Press Release38 views5 min read

Zynerba Pharmaceuticals Presents Longer Term Tolerability and Efficacy Data of Zygel™ in Children and Adolescents with Autism Spectrum Disorder (ASD) at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021

Zynerba Pharmaceuticals
DEVON, Pa., Sept. 09, 2021 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today presented data from the Phase 2 BRIGHT trial describing tolerability and efficacy of Zygel (cannabidiol formulated in a tr... Read More...
Zynerba Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
Press Release65 views2 min read

Zynerba Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

Zynerba Pharmaceuticals
DEVON, Pa., Sept. 02, 2021 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba, will participate in a fireside chat during ... Read More...
Zynerba Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Highlights
FinancialsPress Release64 views35 min read

Zynerba Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Highlights

Zynerba Pharmaceuticals
On track to initiate RECONNECT, a confirmatory pivotal trial of Zygel™ in patients with FXS, in the third quarter of 2021Positive feedback from FDA clarifies potential path forward in ASDCash runway well into the first half of 2024; $85.8 million at June 30, 2021 DEVON, Pa., Aug. 09, 2021 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), t... Read More...
Zynerba Pharmaceuticals to Present at the Canaccord Genuity 41st Annual Growth Conference
CalendarPress Release42 views1 min read

Zynerba Pharmaceuticals to Present at the Canaccord Genuity 41st Annual Growth Conference

Zynerba Pharmaceuticals
DEVON, Pa., Aug. 04, 2021 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Company management will participate in a fireside chat during the Canaccord Genuity 41st Annual Growth Confe... Read More...
Zynerba Pharmaceuticals to Present at the Ladenburg Thalmann Virtual Healthcare Conference
Press Release37 views1 min read

Zynerba Pharmaceuticals to Present at the Ladenburg Thalmann Virtual Healthcare Conference

Zynerba Pharmaceuticals
DEVON, Pa., July 07, 2021 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba, will present a company overview during the L... Read More...
Zynerba Pharmaceuticals Presents Sleep Data from Study of Zygel™ in Children and Adolescents with Both Developmental and Epileptic Encephalopathies (DEE) and Autism Spectrum Disorder (ASD) at the Associated Professional Sleep Societies SLEEP 2021 Annual Meeting
Press Release38 views4 min read

Zynerba Pharmaceuticals Presents Sleep Data from Study of Zygel™ in Children and Adolescents with Both Developmental and Epileptic Encephalopathies (DEE) and Autism Spectrum Disorder (ASD) at the Associated Professional Sleep Societies SLEEP 2021 Annual Meeting

Zynerba Pharmaceuticals
DEVON, Pa., June 11, 2021 -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, presented a poster today at SLEEP 2021, the 35th Annual Meeting of the Associated Professional Sleep Societies, LLC. A copy of th... Read More...
Coming Soon.
IndexLast% Change
S&P 5004,378.411.15%Positive
Euro STOXX 504,334.510.68%Positive
FTSE 1007,493.090.42%Positive
Nikkei 22533,193.992.02%Positive

Delayed data (1h)
IndexLast% Change
S&P 5004,378.411.15%Positive
Euro STOXX 504,334.510.68%Positive
FTSE 1007,493.090.42%Positive
Nikkei 22533,193.992.02%Positive


Share this page






Make smarter investment strategies
with in-depth news reports

Join our subscribers!